MarketPulse

clinical hold

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

REGENXBIO Investors Face April 14 Deadline in Gene Therapy Securities Lawsuit

REGENXBIO faces securities lawsuit over alleged false statements about gene therapy safety. Investors have until April 14 deadline to join class action after FDA clinical hold.
RGNXstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Class Action Lawsuit Filed Against REGENXBIO Over Gene Therapy Safety Disclosures

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.
RGNXsecurities fraudclass action lawsuit